Genomic Health Announces Exclusive Distribution Agreement for Oncotype DX Breast Cancer Assay in United Kingdom

REDWOOD CITY, Calif., June 1, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company signed an exclusive agreement with Medical Solutions plc (LSE: MLS), a healthcare and diagnostics business specializing in diagnostic pathology and cytology services and products, to distribute the company's Oncotype DX breast cancer assay in the United Kingdom.

"We view this U.K. partnership as an important milestone in making our Oncotype DX breast cancer assay more widely available," said Chu Chang, Genomic Health's Vice President of Business Development. "We plan to continue to realize opportunities to broaden access to our test to patients outside of the United States, who may benefit from the individualized information Oncotype DX results provide."

Oncotype DX is currently offered for sale in Israel under a testing and services agreement with Teva Pharmaceutical Industries Ltd., and in Japan under an agreement with SRL, Inc. Patient tumor samples from these and numerous other countries around the world are analyzed in Genomic Health's reference laboratory in Redwood City, California.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

About Medical Solutions plc (LSE: MLS)

Medical Solutions is a fully listed UK based diagnostics and healthcare business specialising in the provision of pathology and cytology services and products to the healthcare, pharmaceutical and biotechnology sectors. It has internationally recognised expertise in histopathology with advanced technology in image analysis, high throughput quantitative protein expression and biomarker determination. For more information about Medical Solutions please visit http://www.medical-solutions.co.uk.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to greater accessibility to our Oncotype DX test as a result of the agreement with Medical Solutions plc and our plans to continue to realize additional opportunities to broaden access to our Oncotype DX test. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; the risks and uncertainties associated with the regulation of our test by FDA; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the three-month period ended March 31, 2007. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc. 

Investors, Brad Cole, +1-650-569-2281, investors@genomichealth.com, or Media, Emily
Faucette, +1-650-569-2824, media@genomichealth.com, both of Genomic Health, Inc.

http://www.genomichealth.com

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

  

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

 

Shareholder Tools

  

DISCLAIMER

The information in the press releases should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.


Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.